Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Hsu, Jingmei  [Clear All Filters]
Journal Article
A Al-Homsi S, Cirrone F, Wo S, Cole K, J Suarez-Londono A, Gardner SL, Hsu J, Stocker K, Bruno B, Goldberg JD, et al. PTCy, Abatacept, and Short Course of Tacrolimus for GvHD Prevention Following Haploidentical Transplantation. Blood Adv. 2023.
Patel C, Pasciolla M, Abramova R, Salerno D, Arteaga AGomez, Shore TB, Orafali N, Mayer S, Hsu J, Phillips AA, et al. Pre-hematopoietic stem cell transplant rituximab for Epstein-Barr Virus and post-transplant lymphoproliferative disorder prophylaxis in alemtuzumab recipients. Transplant Cell Ther. 2022.
Orfali N, Zhang M-J, Allbee-Johnson M, Boelens JJan, Artz AS, Brunstein CG, McNiece IK, Milano F, Abid MB, Chee L, et al. Planned granulocyte-colony stimulating factor adversely impacts survival after allogeneic hematopoietic cell transplantation performed with Thymoglobulin for myeloid malignancy. Transplant Cell Ther. 2021.
Hsu J, Chen Z, Shore T, Gergis U, Mayer S, Phillips A, Guarner D, Hsu M, Cushing MM, van Besien K. OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANT FOR ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES. Biol Blood Marrow Transplant. 2019.
Yi D, Gergis M, Hsu J, Yang Y, Bi X, Aljurf M, Gergis U. Next-Generation Chimeric Antigen Receptor T-cells. Hematol Oncol Stem Cell Ther. 2022;15(3):117-121.
Gomez-Arteaga A, Orfali N, Pasciolla M, Baptiste A, Guindine I, Hsu J, Lin J, Mayer SA, Phillips AA, Shore TB, et al. Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD). Bone Marrow Transplant. 2023.
Bi X, Hsu J, Gergis M, Yang Y, Yi D, Gergis U. Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia. Hematol Oncol Stem Cell Ther. 2022;15(3):131-136.
Yi D, Gergis M, Elgohary G, Hsu J, Yang Y, Bi X, Gergis U. Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement. Hematol Oncol Stem Cell Ther. 2022;15(3):66-72.
Hsu J, Yang Y, Gergis M, Bi X, Yi D, Gergis U. Chimeric Antigen Receptor T Cell Therapy For Solid Tumors. Hematol Oncol Stem Cell Ther. 2022;15(3):94-99.
Yang Y, Bi X, Gergis M, Yi D, Hsu J, Gergis U. Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies. Hematol Oncol Stem Cell Ther. 2022;15(3):112-116.